San Francisco, California - Biotechnology research company ImmuneBridge has raised $12 million in a Seed funding round. Insight Partners, Gaingels, M Ventures, and One Way Ventures are among the investors who participated in this round.

ImmuneBridge is focused on developing allogeneic immunotherapies for cancer. The company's core technology involves expanding cord blood-derived immune stem cells to create a novel, flexible, consistent, and abundant cellular source for immunotherapies. ImmuneBridge is currently working on natural killer cell products for hematological malignancies, with plans to tackle solid tumors using its cellular source's unique advantages.

"We are thrilled to have secured this funding, which will help us to advance our mission of developing innovative allogeneic immune cell therapies for cancer," said ImmuneBridge Co-Founder Peretz Partensky. "With the support of our investors, we can continue to expand our platform and bring new treatments to patients who desperately need them."